Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$155.29 USD

155.29
1,094,683

+0.46 (0.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $155.34 +0.05 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down

Based on a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.

Quest Diagnostics (DGX) Beats Q1 Earnings Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 10.65% and 1.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Quest Diagnostics (DGX) Ahead of Earnings?

Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Quest Diagnostics (DGX) Q1 Earnings to Grow on Base Business

Quest Diagnostics (DGX) is expected to report a strong first half of Q1 with a growing number of cases and then a dull second half on gradual stabilization in testing demand.

Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics (DGX) Inks New Diabetic Retinal Imaging Deal

Quest Diagnostics' (DGX) new collaboration with IRIS will enhance access to diabetic retinopathy screening in the United States.

Quest Diagnostics' (DGX) Volumes Aid, Price Pressure Stays

According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.

Quest Diagnostics' (DGX) New Contract to Aid COVID-19 Research

Quest Diagnostics' (DGX) COVID-19 serological tests, nationwide reach and data analytics capabilities will help assess COVID-19 vulnerability throughout the country.

Is Quest Diagnostics (DGX) a Good Stock for Value Investors?

Let's see if Quest Diagnostics Incorporated (DGX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Quest Diagnostics (DGX) Base Sales Recover Amid Price Woe

Quest Diagnostics (DGX) raises 2022 guidance based on the continued rebound in base business and recent investments expected to accelerate growth.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Quest Diagnostics (DGX) Q4 Revenues Top Estimates, Margins Down

Quest Diagnostics' (DGX) base business revenues grew year over year, achieving record levels in the fourth quarter.

Quest Diagnostics (DGX) Lags Q4 Earnings Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of -0.60% and 0.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Quest Diagnostics (DGX) This Earnings Season?

Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Encompass Health (EHC) Q4 Earnings Lag Estimates

Encompass Health (EHC) delivered earnings and revenue surprises of -8.49% and 1.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics (DGX) COVID Test Sales Aid Amid Price Woe

Quest Diagnostics' (DGX) base business continues to improve, signifying the ongoing recovery trend of the industry.

This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Should You Buy?

Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Quest Diagnostics (DGX) in Q4 Earnings?

In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.

Here's Why You Should Add Quest Diagnostics (DGX) Stock Now

Investors are optimistic about Quest Diagnostics' (DGX) improvement in base business and raised 2021 outlook.

What's in Store for Boston Scientific's (BSX) Q4 Earnings?

On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.

Down 17.9% in 4 Weeks, Here's Why Quest Diagnostics (DGX) Looks Ripe for a Turnaround

Quest Diagnostics (DGX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Quest Diagnostics (DGX) Expands Extended Care With New Buyout

This latest acquisition builds on Quest Diagnostics' (DGX) 2018 acquisition of Mobile Medical Examination Service (MedXM), a provider of home-based health risk assessments and related services.

Quest Diagnostics (DGX) Posts Preliminary Q4 & 2021 Results

Quest Diagnostics (DGX) posts preliminary fourth-quarter and full-year results, reflecting an increase in COVID-19 testing services and a steady recovery in the company's base testing volumes.